Emergent BioSolutions Inc. (0IGA.L)

1,9200 +0,0700 (+3,78%) Alla chiusura: 05:53PM BST

Emergent BioSolutions Inc.

400 Professional Drive
Suite 400
Gaithersburg, MD 20879
United States
240 631 3200
https://www.emergentbiosolutions.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 1.600

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Richard S. Lindahl M.B.A.	Executive VP, CFO & Treasurer	1,02M	N/D	1964
Ms. Jennifer L. Fox	Executive VP of External Affairs, General Counsel & Corporate Secretary	975,84k	N/D	1973
Ms. Coleen Glessner	Executive Vice President of Global Quality and Ethics & Compliance	959,37k	N/D	1971
Mr. Paul A. Williams	Senior Vice President of Products Business	846,97k	N/D	1967
Mr. Joseph C. Papa Jr.	CEO, President & Director	N/D	N/D	1956
Michelle Pepin	Senior VP & Chief Human Resource Officer	N/D	N/D	N/D
Ms. Stephanie Duatschek	Senior VP, Chief Strategy & Transformation Officer	N/D	N/D	N/D
Dr. Kelly Lyn Warfield	Senior VP of Science & Development	N/D	N/D	N/D
William Hartzel	Senior Vice President of Manufacturing & Bioservices	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Governance aziendale

L'ISS Governance QualityScore di Emergent BioSolutions Inc. al 29 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 3; diritti degli azionisti: 7; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.